157 related articles for article (PubMed ID: 20813817)
1. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
Russell MR; Liu Q; Fatatis A
Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.
Matsuo K; Nishimura M; Komurov K; Shahzad MM; Ali-Fehmi R; Roh JW; Lu C; Cody DD; Ram PT; Loizos N; Coleman RL; Sood AK
Gynecol Oncol; 2014 Jan; 132(1):166-75. PubMed ID: 24183729
[TBL] [Abstract][Full Text] [Related]
3. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
[TBL] [Abstract][Full Text] [Related]
4. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
Russell MR; Jamieson WL; Dolloff NG; Fatatis A
Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
[TBL] [Abstract][Full Text] [Related]
5. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
[TBL] [Abstract][Full Text] [Related]
6. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
7. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor.
Dolloff NG; Russell MR; Loizos N; Fatatis A
Cancer Res; 2007 Jan; 67(2):555-62. PubMed ID: 17234763
[TBL] [Abstract][Full Text] [Related]
8. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model.
Böckelmann LC; Freytag V; Ahlers AK; Maar H; Gosau T; Baranowsky A; Schmitz R; Pantel K; Schumacher U; Haider MT; Lange T
Bone; 2023 Jun; 171():116741. PubMed ID: 36934984
[TBL] [Abstract][Full Text] [Related]
11. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
[TBL] [Abstract][Full Text] [Related]
13. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
[TBL] [Abstract][Full Text] [Related]
14. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.
Shah GD; Loizos N; Youssoufian H; Schwartz JD; Rowinsky EK
Cancer; 2010 Feb; 116(4 Suppl):1018-26. PubMed ID: 20127943
[TBL] [Abstract][Full Text] [Related]
15. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
16. Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis.
Liu Q; Jernigan D; Zhang Y; Fatatis A
Chin J Cancer; 2011 Sep; 30(9):612-9. PubMed ID: 21880182
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
[TBL] [Abstract][Full Text] [Related]
19. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
Loizos N; Xu Y; Huber J; Liu M; Lu D; Finnerty B; Rolser R; Malikzay A; Persaud A; Corcoran E; Deevi DS; Balderes P; Bassi R; Jimenez X; Joynes CJ; Mangalampalli VR; Steiner P; Tonra JR; Wu Y; Pereira DS; Zhu Z; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Kussie P
Mol Cancer Ther; 2005 Mar; 4(3):369-79. PubMed ID: 15767546
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer: targeted therapy for prostate cancer metastases to bone.
Coleman R
Nat Rev Urol; 2011 May; 8(6):296-8. PubMed ID: 21587226
[No Abstract] [Full Text] [Related]
[Next] [New Search]